Zobrazeno 1 - 10 of 22 pro vyhledávání: '"Melissa M, Toyos"'
1
Akademický článek
Comparison of Once-Daily Bromfenac 0.07% Versus Once-Daily Nepafenac 0.3% in Patients Undergoing Phacoemulsification
Autor: Melissa M. Toyos
Publikováno v: Ophthalmology and Therapy, Vol 8, Iss 2, Pp 261-270 (2019)
Abstract Aim Randomized pilot study comparing clinical outcomes with bromfenac ophthalmic solution 0.07% versus nepafenac 0.3% ophthalmic suspension administered as identical dosing regimens in patients undergoing uncomplicated phacoemulsification wi
Externí odkaz: https://doaj.org/article/47a99d31c2d0452b909ecaabed759035
Zobrazit plný text záznamu
2
Topical Ocular Anti-TNFα Agent Licaminlimab in the Treatment of Acute Anterior Uveitis: A Randomized Phase II Pilot Study
Autor: Theodore A, Pasquali, Melissa M, Toyos, David B, Abrams, David K, Scales, John W, Seaman, Georges, Weissgerber
Publikováno v: Translational Vision Science & Technology. 11:14
Licaminlimab is a new anti-TNFα antibody fragment for topical ocular application. This phase II study assessed the tolerability, treatment effect, and pharmacokinetics of licaminlimab in acute anterior uveitis (AAU).In this multicenter, randomized,
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5117d17351bd08894d8cbfa3d3c9b978
https://doi.org/10.1167/tvst.11.6.14
Zobrazit plný text záznamu
3
Effect of Oral Re-esterified Omega-3 Nutritional Supplementation on Dry Eyes
Autor: Cynthia Matossian, William J. Faulkner, Frank A. Bucci, Henry D. Perry, Alice T Epitropoulos, Zubin A. Shah, Stephen S. Lane, Melissa M Toyos, Michael B. Gross, Eric D. Donnenfeld, Edward J. Holland
Publikováno v: Cornea
Purpose: To assess the effect of oral re-esterified omega-3 fatty acids on tear osmolarity, matrix metalloproteinase-9 (MMP-9), tear break-up time (TBUT), Ocular Surface Disease Index (OSDI), fluorescein corneal staining, Schirmer score, meibomian gl
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0b544a16c41dcc461fa574644ef44db
https://doi.org/10.1097/ico.0000000000000940
Zobrazit plný text záznamu
4
A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum]
Autor: Joseph Tauber, Barry A Schechter, Jason Bacharach, Melissa M Toyos, Robert Smyth-Medina, Sidney L Weiss, Jodi I Luchs
Publikováno v: Clinical Ophthalmology (Auckland, N.Z.)
Tauber J, Schechter BA, Bacharach J, et al. Clin Ophthalmol.2018;12:1921–1929.On page 1927, “Safety and tolerability assessments” section,third paragraph, first sentence should read from “Fifteensubjects exited the study due to AEs: 5 subject
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8710d4a73b85540407c4ce25d841168e
https://www.dovepress.com/corrigendum2-a-phase-iiiii-randomized-double-masked-vehicle-contr-peer-reviewed-article-OPTH
Zobrazit plný text záznamu
5
Erratum: A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum]
Autor: Joseph Tauber, Barry A Schechter, Jason Bacharach, Melissa M Toyos, Robert Smyth-Medina, Sidney L Weiss, Jodi I Luchs
Publikováno v: Clinical Ophthalmology (Auckland, N.Z.)
Tauber J, Schechter BA, Bacharach J, et al. Clin Ophthalmol. 2018;12:1921–1929.On page 1924, Efficacy end points, Conjunctival staining section, the sentence “Statistically significant reductions in the mean change from baseline in the study eye
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57471808e43fe25c351938c26f2ff031
https://pubmed.ncbi.nlm.nih.gov/30323548
Zobrazit plný text záznamu
6
Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial
Autor: Aparna Raychaudhuri, James H Peace, Kelly K. Nichols, Monica Roy, Melissa M Toyos, Parag A. Majmudar, Amir H. Shojaei, Mohamed Hamdani, Edward J. Holland
Publikováno v: Clinical Ophthalmology (Auckland, N.Z.)
Kelly K Nichols,1 Edward Holland,2 Melissa M Toyos,3 James H Peace,4 Parag Majmudar,5 Aparna Raychaudhuri,6 Mohamed Hamdani,6 Monica Roy,6 Amir Shojaei6 1School of Optometry, University of Alabama at Birmingham, Birmingham, AL, 2Cincinnati Eye Instit
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55902c56882f6aaca55563c61f925023
https://www.dovepress.com/ocular-comfort-assessment-of-lifitegrast-ophthalmic-solution-50-in-opu-peer-reviewed-article-OPTH
Zobrazit plný text záznamu
7
Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial [Corrigendum]
Autor: Kelly Nichols, Edward Holland, Melissa M Toyos, James Peace, Parag Majmudar, Aparna Raychaudhuri, Mohamed Hamdani, Monica Roy, Amir Shojaei
Publikováno v: Clinical Ophthalmology (Auckland, N.Z.)
Purpose To evaluate ocular comfort of lifitegrast ophthalmic solution 5.0% among patients with dry eye disease (DED) in the OPUS-3 trial. Methods OPUS-3 was a multicenter, randomized, double-masked, placebo-controlled study. Adults with DED and recen
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b7b0cdfa912ccf6df7cd8a18acd7a06
https://doi.org/10.2147/opth.s168970
Zobrazit plný text záznamu
9
Akademický článek
Tolerability of Current Treatments for Dry Eye Disease: A Review of Approved and Investigational Therapies.
Autor: Gupta PK; Triangle Eye Consultants, Raleigh, NC, USA.; Department of Ophthalmology, Tulane University, New Orleans, LA, USA., Toyos R; Toyos Clinic, Nashville, TN, USA., Sheppard JD; Virginia Eye Consultants, Norfolk, VA, USA., Toyos M; Toyos Clinic, Nashville, TN, USA., Mah FS; Scripps Clinic, La Jolla, CA, USA., Bird B; Department of Ophthalmology, Eastern Virginia Medical School, Norfolk, VA, USA., Theriot PE; Lusk Eye Specialists, Shreveport, LA, USA., Higgins D; Dry Eye Treatment Center of Connecticut, Plainville, CT, USA.
Publikováno v: Clinical ophthalmology (Auckland, N.Z.) [Clin Ophthalmol] 2024 Aug 16; Vol. 18, pp. 2283-2302. Date of Electronic Publication: 2024 Aug 16 (Print Publication: 2024).
Zobrazit plný text záznamu
10
Akademický článek
Recombinant human nerve growth factor (cenegermin) for moderate-to-severe dry eye: phase II, randomized, vehicle-controlled, dose-ranging trial.
Autor: Wirta D; Eye Research Foundation, 520 Superior Avenue, Suite 235, Newport Beach, CA, 92663, USA., Lipsky W; Advanced Laser Vision & Surgical Institute and Intouch Clinical Research Center, 11550 Fuqua Street, Suite 250, Houston, TX, 77034, USA., Toyos M; Toyos Clinic, 2204 Crestmoor Road, Nashville, TN, 37215, USA., Martel J; Martel Eye Medical Group, 11216 Trinity River Drive, Rancho Cordova, CA, 95670, USA., Goosey J; Houston Eye Associates, 2855 Gramercy Street, Houston, TX, 77025, USA., Verachtert A; Moyes Eye Center, 5151 NW 88 Street, Kansas City, MO, 64154, USA., El-Harazi S; Global Research Management, 1510 S Central Avenue, Glendale, CA, 91204, USA., Karpecki P; Kentucky Eye Institute, 601 Perimeter Drive, Suite 100, Lexington, KY, 40517, USA., Allegretti M; Dompé farmaceutici S.p.A, Via Santa Lucia 6, Milan, 20122, Italy., Goisis G; Dompé farmaceutici S.p.A, Via Santa Lucia 6, Milan, 20122, Italy., Pasedis G; Dompé farmaceutici S.p.A, Via Santa Lucia 6, Milan, 20122, Italy., Mantelli F; Dompé farmaceutici S.p.A, Via Santa Lucia 6, Milan, 20122, Italy. flavio.mantelli@dompe.com.
Publikováno v: BMC ophthalmology [BMC Ophthalmol] 2024 Jul 17; Vol. 24 (1), pp. 290. Date of Electronic Publication: 2024 Jul 17.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje